Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination

Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination

Homero Contreras-Salinas,1 Mariana Barajas-Hernández,1 Leopoldo Martín Baiza-Durán,1 Alan Omar Vázquez-Álvarez,2 Manuel Alejandro Bautista-Castro,1 Lourdes Yolotzin Rodríguez-Herrera1 1Pharmacovigilance Department, Laboratorios Sophia...

Full description

Bibliographic Details
Main Authors:	Contreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Vázquez-Álvarez AO, Bautista-Castro MA, Rodríguez-Herrera LY
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-02-01
Series:	Clinical Ophthalmology
Subjects:	adverse drug reactions active pharmacovigilance surveillance glaucoma timolol/brimonidine/dorzolamide.
Online Access:	https://www.dovepress.com/active-pharmacovigilance-in-peruvian-population-surveillance-of-a-timo-peer-reviewed-article-OPTH

Similar Items

Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination [Erratum]
by: Contreras-Salinas H, et al.
Published: (2022-02-01)

Comparative study of brimonidine and timolol in treatment of glaucoma
by: Jagadish Chandrarao Narasaiah Lakkineni
Published: (2015-01-01)

Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study
by: Mary S Galose, et al.
Published: (2016-01-01)

Intraocular pressure-lowering effects of commonly used fixed combination drugs with timolol in the management of primary open angle glaucoma
by: Murat Atabey Ozer, et al.
Published: (2014-10-01)

Antioxidant activity of dorzolamide/timolol fixed combination in neuroprotective therapy in glaucoma
by: N. I. Kurysheva, et al.
Published: (2014-07-01)

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma
by: Prerana Agarwal, et al.
Published: (2022-01-01)

Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/timolol in patients with primary open-angle glaucoma and ocular hypertension
by: Babić Nikola, et al.
Published: (2013-01-01)

Effects of dorzolamide/timolol fixed combination on retrobulbar hemodynamics in pseudoexfoliative glaucoma
by: Mustafa Eliacik, et al.
Published: (2016-01-01)

Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection
by: Sehnaz Ozcaliskan, et al.
Published: (2015-06-01)

Effect of brimonidine tartrate on basophil activation in glaucoma patients
by: Eldar Rosenfeld, et al.
Published: (2020-03-01)

Successful treatment of ulcerated infantile hemangioma with brimonidine-timolol cream: 2 cases report and review of the literature
by: Mishal Almebayadh
Published: (2020-05-01)

Efeitos maleato de timolol 0.5% do cloridrato de dorzolamida 2%, e da associação de ambas na pressão intra-ocular Efficacy of timolol maleate 0.5% dorzolamide hydrochloride 2%, and the combination of both drugs on intraocular pressure
by: A.G. Borges, et al.
Published: (2007-06-01)

Prolonged central nervous system and respiratory depression in preterm neonates after exposure to brimonidine tartrate and timolol maleate ophthalmic drops
by: Azarcon, Corrina P., et al.
Published: (2020-05-01)

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
by: Sang-Woo Park, et al.
Published: (2022-02-01)

Effects of Latanoprost 0.005%/Timolol Maleate 0.5% and Dorzolamide 2%/Timolol Maleate 0.5% Fixed Combinations on 24-hour Intraocular Pressure in Patients with Primary Open-Angle Glaucoma
by: Berna Yüce, et al.
Published: (2012-01-01)

Ocular Co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
by: Elissavet Taka, et al.
Published: (2020-06-01)

Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs
by: Gen Suzuki, et al.
Published: (2020-01-01)

Neuroprotective properties of Brimonidine
by: Т. N. Mikhailova
Published: (2019-11-01)

Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
by: Yoshikawa K, et al.
Published: (2021-07-01)

The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients
by: Hiromitsu Onoe, et al.
Published: (2022-12-01)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
by: Lerner SF, et al.
Published: (2019-12-01)

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
by: Hiromitsu Onoe, et al.
Published: (2021-11-01)

The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations
by: Ruiz Simonato Alonso, et al.
Published: (2020-03-01)

Brimonidine-associated uveitis – a descriptive case series
by: Susanne Hopf, et al.
Published: (2020-12-01)

Acute serous and hemorrhagic choroidal effusion associated with topical dorzolamide therapy
by: Abdulla Shaheen, et al.
Published: (2023-09-01)

Efficacy and safety of various brimonidine formulations in the treatment of glaucoma and ocular hypertension
by: A. V. Sidorova, et al.
Published: (2021-07-01)

Bilateral Choroidal Detachment in the Absence of Previous Intraocular Surgery
by: Maria J. Chaves-Samaniego, et al.
Published: (2022-09-01)

Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy
by: Oya Tekeli, et al.
Published: (2022-08-01)

Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial
by: Anubha Bhatti, et al.
Published: (2018-01-01)

Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China
by: Sun XH, et al.
Published: (2017-04-01)

Timolol maleate 0.5% versus timolol maleate in gel forming solution 0.5% (timolol GFS) in open angle glaucoma in India. Preliminary safety and efficacy study
by: Kumar Harsh, et al.
Published: (2002-01-01)

Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits
by: Kamaruddin MI, et al.
Published: (2017-03-01)

Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes
by: Thomas Ravi, et al.
Published: (2003-01-01)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
by: Baiza-Dur&aacute;n LM, et al.
Published: (2012-07-01)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
by: Kozobolis V, et al.
Published: (2018-11-01)

A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension
by: Tao Wang, et al.
Published: (2022-11-01)

A Comparison of Ocular Hypotensive Response to Betaxolol and Timolol And Their Topical and Systemic Side Effects
by: M. Samavati, M.D
Published: (2007-09-01)

Symptomatic Bradycardia and Syncope due to Ophthalmic Timolol Maleate
by: Muge Gulen, et al.
Published: (2014-08-01)

Dramatic response to topical dorzolamide in X-linked retinoschisis
by: Rajeswari Thangavel, et al.
Published: (2020-01-01)

Difference in vasoconstrictors: oxymetazoline vs. brimonidine
by: Nwanneka Okwundu, et al.
Published: (2021-02-01)